Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, confirms that further to the announcement of the £3.25m equity financing on 17 July 2025 (the “Placing”) that it has settled the quarterly principal of £2.55 million and interest repayment of c.£0.414 million in respect of the Company’s unsecured convertible bond in cash. The Placing is due to complete on 24 July 2025.
After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by £2.55 million to £22.95 million.